Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume – Time to Buy?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) shares saw unusually-high trading volume on Tuesday . Approximately 448,209 shares traded hands during trading, a decline of 5% from the previous session’s volume of 472,318 shares.The stock last traded at $15.01 and had previously closed at $15.43.

Silence Therapeutics News Roundup

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Silence Therapeutics reported positive top-line results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent patients with polycythemia vera. The treatment met its primary and secondary endpoints, supporting management’s view that divesiran could have a best-in-class profile and strengthening the company’s lead clinical program. Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial
• Positive Sentiment: The trial outcome triggered investor optimism and a sharp move higher in the stock, with coverage highlighting the potential of divesiran to treat polycythemia vera and other blood disorders. Management discussed the results in an investor presentation and conference-call transcript. Silence Therapeutics stock surges as divesiran trial results fuel optimism
• Neutral Sentiment: Analysts assigned Silence Therapeutics a consensus “Moderate Buy” rating, indicating generally favorable expectations but not unanimous bullish conviction. Silence Therapeutics Given Consensus Rating of Moderate Buy
• Negative Sentiment: The company launched a proposed underwritten public offering of approximately $150 million of American Depositary Shares. While the proceeds could support clinical development, the offering may dilute existing shareholders and create near-term selling pressure. Silence Therapeutics Announces Proposed Public Offering
• Negative Sentiment: Second-quarter results were weaker than expected: Silence reported a loss of $0.26 per share versus the $0.14 consensus loss estimate. The company remains unprofitable, increasing the importance of financing and successful development of its pipeline. Silence Therapeutics Reports Second Quarter 2026 Results

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Cantor Fitzgerald began coverage on Silence Therapeutics in a report on Wednesday, June 24th. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $32.00 target price (up from $25.00) on shares of Silence Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Silence Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $53.50.

Silence Therapeutics Stock Performance

The company has a market cap of $733.87 million, a price-to-earnings ratio of -9.70 and a beta of 1.39. The company’s 50 day moving average price is $9.49 and its 200 day moving average price is $7.25.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. As a group, analysts predict that Silence Therapeutics PLC Sponsored ADR will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Boothbay Fund Management LLC raised its position in Silence Therapeutics by 1.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares during the last quarter. Massar Capital Management LP bought a new position in shares of Silence Therapeutics during the 2nd quarter worth approximately $115,000. UBS Group AG raised its holdings in shares of Silence Therapeutics by 34.5% in the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after purchasing an additional 78,854 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after purchasing an additional 3,935 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics in the third quarter worth $112,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.